Benjamin Goldenson

TL;DR: The functions of each Aurora kinase are described, their involvement in leukemia is summarized, small-molecule inhibitors of Aurora kinases as leukemia therapies are discussed and inhibitor development and efficacy in leukemia clinical trials are discussed.

TL;DR: In this article, a high-content image-based screen was used to identify small-molecule probes that induce polyploidization of megakaryocytic leukemia cells and serve as perturbagens to help understand this process.

TL;DR: It is suggested that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit, and heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo.

TL;DR: Findings establish AKT as a rational therapeutic target in the MPNs by showing that inhibition of PI3K/AKT signaling by MK-2206 affected the growth of both JAK2V617F- or MPLW515L-expressing cells via reduced phosphorylation of AKT and inhibition of its downstream signaling molecules.

TL;DR: This ERG/Gata1s transgenic mouse model uncovers an essential role for the N terminus of Gata1 in erythropoiesis and the antagonistic role of ERG in fetal erythroid differentiation and survival.